RCE — Recce Pharmaceuticals Cashflow Statement
0.000.00%
- AU$118.23m
- AU$118.53m
- AU$7.70m
- 14
- 26
- 42
- 15
Annual cashflow statement for Recce Pharmaceuticals, fiscal year end - June 30th, AUD millions except per share, conversion factor applied.
2021 June 30th | 2022 June 30th | 2023 June 30th | C2024 June 30th | 2025 June 30th | |
---|---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
Source: | ARS | ARS | ARS | ARS | ARS |
Standards: | IFRS | IFRS | IFRS | IFRS | IFRS |
Status: | Final | Final | Final | Final | Final |
Changes in Working Capital | 0.215 | 0.08 | -1.3 | 0.23 | 0.778 |
Other Operating Cash Flow | |||||
Cash from Operating Activities | -7.86 | -9.01 | -12.7 | -13 | -20.4 |
Capital Expenditures | -0.076 | -0.04 | -0.039 | -0.142 | -0.026 |
Purchase of Fixed Assets | |||||
Other Investing Cash Flow Items | — | — | — | -0.163 | -0.418 |
Change in Net Investments | |||||
Other Investing Cash Flow | |||||
Cash from Investing Activities | -0.076 | -0.04 | -0.039 | -0.305 | -0.444 |
Financing Cash Flow Items | -1.76 | -0.389 | -0.104 | -0.563 | -1.74 |
Other Financing Cash Flow | |||||
Net Issuance / Retirement of Stock | |||||
Net Issuance / Retirement of Debt | |||||
Cash from Financing Activities | 26.1 | -0.24 | 2.71 | 16.2 | 26.9 |
Beginning Cash Balance | |||||
Ending Cash Balance | |||||
Net Change in Cash | 18.2 | -9.29 | -10 | 2.85 | 6.03 |